Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : scores $260M+ DOD orthopedics contract

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2017 | 10:39am CEST

The Department of Defense awarded Johnson & Johnson a contract worth up to $260.5 million to supply it with orthopedic products.

The deal will see J&J providing orthopedic products to the Army, Navy, Air Force, Marine Corps and the DODs federal civilian agencies, according to a statement. The one-year agreement could be extended one year at a time for another four years, the DOD said.

In the first quarter, J&J reported (PDF) $6.3 billion in medical device sales for the first quarter, with its Orthopaedics group and Surgery units leading the pack. The Orthopaedics business, which includes hips, knees, trauma and spine, reeled in $2.33 billion in sales, slightly down from the $2.34 billion reported the previous year.

The company reported 2.3% growth in its knee business, largely due to uptake of its Attune Knee System in China, the Middle East and Africa. Its hip unit posted 2.9% growth, thanks to a product launch in China and continued uptake of its CORAIL hip system in the U.S. Meanwhile, its trauma segment remained flat with $642 million, mirroring its sales a year prior, and with $933 million in sales, its spine group was down 3.6% from the $968 million it reported in Q1 2016.

Outside of orthopedics, J&J revealed it was pondering what to do with its diabetes device businesses, with joint ventures, operating partnerships and/or divestitures on the table. These businesses are the insulin pump maker Animas, Lifescan, which makes blood glucose monitors, and Calibra, which makes a mealtime insulin patch.

At the time, Chief Financial Officer Dominic Caruso said pricing pressure led to the new considerations. The diabetes pricing over the last several years has been challenging and although I think our team has done a nice job of adjusting the cost structure, the level of profitability that business has declined, he said.

But J&J hasnt made a move yet and is still mulling its options, Caruso said on the 2017 first-quarter earnings call.

(c) 2003-2017 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
10:39a JOHNSON & JOHNSON : scores $260M+ DOD orthopedics contract
04/28 JOHNSON & JOHNSON : Janssen Research & Development Submits Supplemental New Drug..
04/28 JOHNSON & JOHNSON : How Johnson & Johnson Is Leading When It Comes to Military L..
04/28 ACTELION : Publication of the definitive notice of the end result of Actelion te..
04/28 JOHNSON & JOHNSON : European Commission Extends Approval for Janssen’s DAR..
04/28 JOHNSON & JOHNSON : Sharon Kleyne & Neville L. Johnson Explore Privacy & Bullies..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 DAILY DIVIDEND REPORT : Xom, jnj, su, xlnx, pfe, cvx, ko
04/27 JOHNSON & JOHNSON : Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance..
04/27 JOHNSON & JOHNSON : Announces Dividend Increase of 5.0%
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:00a RETIREMENT STRATEGY : You've Saved, Invested, And Retired. Now What?
04/28 JOHNSON & JOHNSON : 55 Years Of Increasing Dividends, A Company For All Seasons
04/28 HOW TO POSITION YOUR PORTFOLIO FOR T : 3 Actionable Steps
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 Calling All Heart Docs - Your Diabetes Drugs Need You
Advertisement
Financials ($)
Sales 2017 75 666 M
EBIT 2017 23 472 M
Net income 2017 17 913 M
Debt 2017 8 242 M
Yield 2017 2,73%
P/E ratio 2017 18,82
P/E ratio 2018 16,91
EV / Sales 2017 4,53x
EV / Sales 2018 4,33x
Capitalization 334 714 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 129 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
SANOFI11.79%121 897
More Results